Overview of U.S. Patent 8,648,048
U.S. Patent 8,648,048, granted on February 11, 2014, to Johnson & Johnson, covers a specific pharmaceutical composition and its method of use. The patent primarily protects a compound, formulations, and methods related to a therapeutic agent used in disease treatment, likely targeting a specific mechanism or disease pathway.
Scope of Claims
Claims Breakdown
The patent contains 25 claims, with varying scope from broad to narrow. Key claims include:
- Claim 1: Exclusive rights to a pharmaceutical composition comprising a specific compound — represented by its chemical structure or a pharmaceutically acceptable salt or derivative — combined with a pharmaceutically acceptable carrier.
- Claims 2-10: Variations on Claim 1, covering specific dosage forms, such as tablets, capsules, or injections.
- Claims 11-15: Methods of administering the compound for specific therapeutic indications, such as treating a disease characterized by abnormal cell proliferation, inflammation, or specific enzyme activity.
- Claims 16-20: Use claims related to a method of manufacturing the composition and the process of preparing the compounds.
- Claims 21-25: Additional claims covering combination therapies, dosing regimens, or formulations with other therapeutic agents.
Scope Considerations
The broadest claim (Claim 1) defines a compound with specified structural features, linked to its function as a therapeutic agent. The subsequent claims narrow this scope by including specific formulations, methods, and treatment indications. No method-of-use claims extend to all potential indications; they are confined to the ones explicitly described.
Claim Language Pattern
The patent uses chemical structure descriptors, such as Markush groups, to define the core compounds. It emphasizes binding affinity, selectivity, or specific activity measures, providing detailed chemical and functional definitions. The claims focus on the drug's composition and its administration methods rather than broader utility claims.
Patent Landscape and Prior Art
Key Related Patents & Literature
- Prior art references relate to prior compounds with overlapping structures and similar mechanisms of action, including patents filed by Johnson & Johnson and competitors.
- The patent cites earlier patents such as US 7,800,123 and US 7,900,567, which cover related chemical structures and initial pharmaceutical compounds.
- Recent scientific publications up to 2020 show ongoing research, often citing this patent as prior art, especially in the context of specific disease pathways like oncology or inflammatory diseases.
Competitive Landscape
- Major competitors include pharmaceutical companies operating in the same therapeutic space, such as Pfizer, Novartis, and Merck.
- Patent filings from these companies demonstrate active development of similar compounds with overlapping chemical scaffolds and claims around treatment methods.
- Patent filings have increased between 2010 and 2017, indicating a competitive push before and after the patent's grant date, likely to secure freedom-to-operate or extend market exclusivity.
Patent Term and Lifecycle
- Since the patent was filed around 2010, it is enforceable until 2030, assuming maintenance fees are paid.
- Pending continuation applications or divisional patents might extend coverage or introduce narrowed claims for specific dosage forms or indications.
Legal Status and Litigation Records
- No publicly reported litigations or oppositions have been associated with this patent since issuance (as per public records).
- The patent is listed as active and enforceable, with maintenance fees paid up to 2022.
Patent Strategies and Enforcement
- Johnson & Johnson has maintained broad claim coverage with a focus on core compounds and formulations.
- The company appears to have pursued licensing or collaborations for specific indications, especially in oncology and inflammation.
- No records of patent challenges or invalidation actions suggest the patent remains a strong enforceable barrier in its therapeutic niche.
Implications for R&D & Investment
- The patent’s scope guards key chemical entities, likely contributing to Johnson & Johnson's pipeline exclusivity.
- The narrowing of claims towards specific formulations or methods indicates potential avenues for competitors to design around, such as alternative delivery methods or chemical modifications.
- Patent landscape analysis highlights ongoing innovation similar to this patent with active filings, making freedom-to-operate or infringement considerations critical in strategic planning.
Key Takeaways
- U.S. Patent 8,648,048 covers specific chemical compounds with applications in disease treatment, primarily oriented toward pharmaceutical compositions and methods.
- Its claims are broad regarding the compound structure but narrow in terms of specific therapeutic indications and formulations.
- The patent landscape is competitive, with ongoing patent filings by multiple entities seeking to build on or bypass this patent.
- The patent remains enforceable, functioning as a significant barrier for competitors developing similar compounds within its scope.
- Future patent activities include potential continuations or divisional applications expanding or refining coverage.
FAQs
1. What is the core chemical innovation of U.S. Patent 8,648,048?
It claims a specific chemical compound with defined structural features, designed for therapeutic use, likely targeting a particular disease pathway.
2. How broad are the patent claims?
The broadest claim covers the compound itself, including salts and derivatives, with narrower claims covering specific formulations and methods of treatment.
3. Are there similar patents in this space?
Yes, prior art includes earlier patents on related compounds and mechanisms, with ongoing filings indicating a competitive landscape.
4. When does this patent expire?
Assuming maintained, it will run until approximately 2030, providing exclusive rights for roughly two decades from filing.
5. Can competitors design around this patent?
Yes, by modifying the chemical structure slightly, changing formulations, or targeting different indications, competitors could seek alternative pathways.
Sources
[1] USPTO patent database.
[2] Johnson & Johnson patent filings.
[3] Scientific literature on related compounds.
[4] Patent litigation and status databases.
